Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kantharaj Ethirajulu

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Drug Metabolism Letters|January 21, 2015
Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and HumansRamesh Jayaraman, Mohammed Khalid Pasha, Anthony Williams, et al.
Journal of Medicinal Chemistry|October 28, 2005
MetaSite: understanding metabolism in human cytochromes from the perspective of the chemistGabriele Cruciani, Emanuele Carosati, Benoit De Boeck, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 11, 2012
SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritisBabita Madan, Kee Chuan Goh, Stefan Hart, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 30, 2011
Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokineticsRamesh Jayaraman, Venkatesh Pilla Reddy, Mohammed Khalid Pasha, et al.
Molecular Cancer Therapeutics|May 19, 2011
Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissueVeronica Novotny-Diermayr, Nina Sausgruber, Yung Kiang Loh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypesAnas Younes, Jorge Romaguera, Michelle Fanale, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2012
2-anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1Stéphanie Blanchard, Chang Kai Soh, Chai Ping Lee, et al.
Molecular Cancer Therapeutics|March 4, 2010
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancerVeronica Novotny-Diermayr, Kanda Sangthongpitag, Chang Yong Hu, et al.
Vaccine|July 22, 2014
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteersJenny G H Low, Lawrence S Lee, Eng Eong Ooi, et al.
Clinical and Translational Science|July 26, 2019
First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology DrugVincenzo Teneggi, Veronica Novotny-Diermayr, Lay Hoon Lee, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Drug Metabolism Letters|January 21, 2015
Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and HumansRamesh Jayaraman, Mohammed Khalid Pasha, Anthony Williams, et al.
Journal of Medicinal Chemistry|October 28, 2005
MetaSite: understanding metabolism in human cytochromes from the perspective of the chemistGabriele Cruciani, Emanuele Carosati, Benoit De Boeck, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 11, 2012
SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritisBabita Madan, Kee Chuan Goh, Stefan Hart, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 30, 2011
Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokineticsRamesh Jayaraman, Venkatesh Pilla Reddy, Mohammed Khalid Pasha, et al.
Molecular Cancer Therapeutics|May 19, 2011
Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissueVeronica Novotny-Diermayr, Nina Sausgruber, Yung Kiang Loh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypesAnas Younes, Jorge Romaguera, Michelle Fanale, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2012
2-anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1Stéphanie Blanchard, Chang Kai Soh, Chai Ping Lee, et al.
Molecular Cancer Therapeutics|March 4, 2010
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancerVeronica Novotny-Diermayr, Kanda Sangthongpitag, Chang Yong Hu, et al.
Vaccine|July 22, 2014
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteersJenny G H Low, Lawrence S Lee, Eng Eong Ooi, et al.
Clinical and Translational Science|July 26, 2019
First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology DrugVincenzo Teneggi, Veronica Novotny-Diermayr, Lay Hoon Lee, et al.
Pageof 2